Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
The American labor market is experiencing a fascinating dichotomy as it navigates late 2024 and 2025. While overall job creation has shown signs of moderation and significant revisions to earlier optimistic figures, a robust undercurrent of growth is emerging from the nation's manufacturing sector. This resurgence, largely driven by substantial
New York, NY – December 9, 2025 – The S&P 500 Healthcare sector found itself in a precarious position today, emerging as the biggest underperformer among its peers. While the broader S&P 500 index largely treaded water, the healthcare segment registered a notable decline of 0.5%, extending a three-day
As global trade tensions escalate dramatically throughout late 2024 and 2025, marked by a surge in protectionist policies and tit-for-tat tariffs, silver has emerged as a dual-threat asset: a critical safe-haven for investors fleeing economic uncertainty and a strategic industrial metal indispensable to the burgeoning green and high-tech economies. With
Global financial markets are treading a cautious path as December 9, 2025, unfolds, with investors keenly focused on the impending U.S. Federal Reserve's interest rate decision. The highly anticipated move, expected to be a 25-basis-point cut, is poised to reshape monetary policy landscapes, while persistent geopolitical tensions and the
JPMorgan Chase & Co. (NYSE: JPM), a titan of the financial industry and a significant component of the Dow Jones Industrial Average (DJIA), recently experienced a notable shift in market sentiment. Despite a year of robust financial performance characterized by surging earnings and revenue growth throughout 2024 and 2025, a cautious
Eli Lilly and Co (NYSE: LLY) announced that its diabetes drug, Mounjaro, will be added to China's state-run health insurance scheme from January 1, 2026.
Eli Lilly offers a stable, growing dividend backed by exceptional profitability and solid financial health, making it a prime pick for long-term dividend growth investors.
JACKSONVILLE BEACH, Fla., Dec. 4, 2025 (SEND2PRESS NEWSWIRE) -- Industrial SalesLeads today announced the findings of its November 2025 report on planned capital project spending within the North American Industrial Manufacturing sector. The firm's research, which tracks new plant construction, facility expansions, and significant equipment modernization, identified 154 new projects. Capital project activity remains stable, with 154 new projects in November, nearly matching the 155 projects tracked in October.
Despite Agilent Technologies’ underperformance relative to its industry peers, Wall Street analysts remain moderately optimistic about the stock’s prospects.
